Analyzing ENDRA Life Sciences (NDRA) and The Competition

ENDRA Life Sciences (NASDAQ: NDRA) is one of 48 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare ENDRA Life Sciences to similar companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares ENDRA Life Sciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ENDRA Life Sciences N/A -326.97% -233.06%
ENDRA Life Sciences Competitors -277.66% -137.74% -18.75%

Earnings and Valuation

This table compares ENDRA Life Sciences and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ENDRA Life Sciences $10,000.00 -$9.80 million -0.91
ENDRA Life Sciences Competitors $1.21 billion $130.98 million 20.83

ENDRA Life Sciences’ peers have higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

ENDRA Life Sciences has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences’ peers have a beta of 1.40, suggesting that their average stock price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ENDRA Life Sciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences 0 0 2 0 3.00
ENDRA Life Sciences Competitors 246 678 1286 61 2.51

As a group, “Electromedical equipment” companies have a potential upside of 25.45%. Given ENDRA Life Sciences’ peers higher possible upside, analysts plainly believe ENDRA Life Sciences has less favorable growth aspects than its peers.

Insider and Institutional Ownership

17.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 43.9% of shares of all “Electromedical equipment” companies are held by institutional investors. 11.4% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 15.9% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ENDRA Life Sciences peers beat ENDRA Life Sciences on 10 of the 13 factors compared.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.